0001193125-23-277950.txt : 20231115 0001193125-23-277950.hdr.sgml : 20231115 20231115165002 ACCESSION NUMBER: 0001193125-23-277950 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231110 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20231115 DATE AS OF CHANGE: 20231115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERU INC. CENTRAL INDEX KEY: 0000863894 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 391144397 STATE OF INCORPORATION: WI FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13602 FILM NUMBER: 231411239 BUSINESS ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 BUSINESS PHONE: 3125959123 MAIL ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: FEMALE HEALTH CO DATE OF NAME CHANGE: 19960205 FORMER COMPANY: FORMER CONFORMED NAME: WISCONSIN PHARMACAL COMPANY INC DATE OF NAME CHANGE: 19920703 8-K 1 d850611d8k.htm 8-K 8-K
NASDAQ false 0000863894 0000863894 2023-11-10 2023-11-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2023

 

 

VERU INC.

(Exact name of registrant as specified in its charter)

 

 

 

Wisconsin   1-13602   39-1144397
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   VERU   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 4.02

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

(a)    On November 10, 2023, in connection with the preparation of consolidated financial statements for the year ended September 30, 2023, Veru Inc. (the “Company”) concluded that its previously issued unaudited condensed consolidated financial statements as of and for the three and nine months ended June 30, 2023 (the “Prior Financial Statements”) should no longer be relied upon due to the identification of an error related to the accounting for the sale of ENTADFI assets on April 19, 2023, for which a gain on sale of $17,456,814 was initially recorded. The Company has determined that it was not probable, at the time of the transaction, that substantially all of the consideration promised under the asset purchase agreement would be collected. Notes receivable in the aggregate principal amount of $14.0 million, and related imputed interest, issued pursuant to the sale of the ENTADFI assets on April 19, 2023, should not have been recorded in the financial statements due to the uncertainty in the collectability of these amounts. The consideration for the transaction should have only included the $6.0 million of cash received by the Company at closing. The corrected gain on the sale of ENTADFI assets should have been $4,723,623.

The Company also determined that there was an error in the going concern disclosures in the Prior Financial Statements. Specifically the Company considered if the forecasted future cash flows will be sufficient to enable the Company to meet its contractual commitments and obligations as they come due in the ordinary course of business for a period of at least one year from the filing of the Company’s report on Form 10-Q for the quarter ended June 30, 2023 on August 10, 2023. The collectability of the notes receivable and certain planned capital transactions were included in those cash flows but are not within the control of management and cannot be relied upon for the purposes of the going concern assessment. Therefore, the Company concluded there is substantial doubt about the Company’s ability to continue as a going concern and there is an error in the going concern disclosures included in the Company’s report on Form 10-Q filed August 10, 2023 as will be described in the Amended Quarterly Report (as defined below).

The Company has assessed the materiality of these errors in accordance with applicable rules of the U.S. Securities and Exchange Commission (the “SEC”), and has concluded that the Prior Financial Statements should be restated. The Company intends to include the restated Prior Financial Statements in an amended Quarterly Report on Form 10-Q/A (the “Amended Quarterly Report”) to be filed with the SEC. As a result of the restatement of the Prior Financial Statements, management has determined that a material weakness exists in the Company’s internal control over financial reporting related to its controls over applying technical accounting guidance to nonrecurring events and transactions, specific to the evaluation of information that was known or knowable at the time of the transaction or event. The identified material weakness and the Company’s remediation plan will be described in the Amended Quarterly Report to be filed with the SEC.

The Audit Committee of the Company’s Board of Directors has discussed the matters disclosed in this Current Report on Form 8-K with RSM US LLP, the Company’s independent registered public accounting firm.

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are often, but are not always, made through the use of words or phrases such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue,” and similar expressions, or the negative of these terms, or similar expressions. These forward-looking statements include, but are not limited to, statements regarding the expectations, hopes, beliefs, intentions or strategies of the Company regarding the future including, without limitation, statements regarding: (i) the plan to remediate the material weakness identified in this Current Report on Form 8-K, including whether such remediation plan will be effective at preventing or avoiding potential future significant deficiencies or material weaknesses in the Company’s internal control over financial reporting, or prevent or detect a misstatement of the Company’s accounts or disclosures that could result in a material misstatement of our annual or interim financial statements; (ii) the timing of the Company’s filing of the Amended Quarterly Report with the SEC; and (iii) the potential impacts of items discussed in this Current Report on Form 8-K on the Company’s business, results of operations, cash flows, liquidity, financial condition and ability to execute its strategic business plan. These statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them, including: the risk that the Company may identify new material weaknesses in the future or will not be able to successfully remediate the material weakness identified in this Current Report on Form 8-K and related deficiencies in the Company’s disclosure controls and procedures, and that the accuracy and timing of the Company’s financial reporting may be adversely affected; and the risk that investors may lose confidence in the accuracy and completeness of the Company’s financial reports, which could harm the Company’s reputation, cause the market price of the Company’s common stock to decline, subject the Company to sanctions or investigations by the SEC or other regulatory authorities, and adversely impact the Company’s ability to source external financing for the Company’s capital needs on acceptable terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 and other documents filed by the Company from time to time with the SEC. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 15, 2023   VERU INC.
    By:  

/s/ Michele Greco

      Michele Greco
     

Chief Financial Officer and

Chief Administrative Officer

 

3

EX-101.SCH 2 veru-20231110.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 veru-20231110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 1 Entity Address Address Line 2 Entity Address Address Line 2 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 4 veru-20231110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 10, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 10, 2023
Entity Registrant Name VERU INC.
Entity Incorporation State Country Code WI
Entity File Number 1-13602
Entity Tax Identification Number 39-1144397
Entity Address Address Line 1 2916 N. Miami Avenue
Entity Address Address Line 2 Suite 1000
Entity Address City Or Town Miami
Entity Address State Or Province FL
Entity Address Postal Zip Code 33127
City Area Code 305
Local Phone Number 509-6897
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol VERU
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000863894
XML 6 d850611d8k_htm.xml IDEA: XBRL DOCUMENT 0000863894 2023-11-10 2023-11-10 NASDAQ false 0000863894 8-K 2023-11-10 VERU INC. WI 1-13602 39-1144397 2916 N. Miami Avenue Suite 1000 Miami FL 33127 305 509-6897 false false false false Common Stock, $0.01 par value per share VERU false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000001 - Document - Document and Entity Information Sheet http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d850611d8k.htm veru-20231110.xsd veru-20231110_lab.xml veru-20231110_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d850611d8k.htm": { "nsprefix": "veru", "nsuri": "http://verupharma.com/20231110", "dts": { "inline": { "local": [ "d850611d8k.htm" ] }, "schema": { "local": [ "veru-20231110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "veru-20231110_lab.xml" ] }, "presentationLink": { "local": [ "veru-20231110_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-10_to_2023-11-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d850611d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-10_to_2023-11-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d850611d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://verupharma.com//20231110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "terseLabel": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-23-277950-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-277950-xbrl.zip M4$L#!!0 ( $"&;U<2T">W\14 #=Q . 9#@U,#8Q,60X:RYH=&WM M7>M3&SFV_WZK[O^@\LSL0I7?-@1,PA9#R"P["6& [$S=+RFY6[:U:;=ZI&[ M^]??),*]JDS1-!JW6SK"'>M<@?N%W5M@-M8YBJ^./GB[=% M\W1Y^Z)I*]4\-B,%'$A!L,B!=J/=;72ZI4X:1@25CN![:2,7-P''$SI%[]G4ISH]-5 M[?-;Y0=6XQ5UHD;*(7B(OU.91N)PK_'KRY;]"->F(N4,>VB(/S-Y_:IVK.)4 MQ&GC"@:JLU5+Q6W:HAY9"Y]KN4X98R^'*IP=O@SE-3/I+!*O:J$T2<1G M@UC%HG;(7LK; 387VGV682AB^QF:G&53H67 9/BJ]G>Z]1%X^/%2!)F6Z>SD M-ICP>"S.^!0(BN$G#"#D8/E](O@VO1 C:)5I L9'9%>CTVETVA]35?I6.SP[ MNGQ]]-O+5H62NR@[FHHXA/_3-Q$??[Q[E!+1E4(!Z\*IFY#2)4'OIVD0C*6A>&]ZH-F]-Z&]S'6B%\+RWV7X"AW#XLE6= MCYM]9<;TW:A,VZ]DQ0:.W23?>[#;/R9(>/E7&>*%D12:$0EBJ8T]/OVU*K#Y MAY'JI?TG(%$5YE_!O.KT-4_%84&;?[*X5] :KFCK[^3#YN.T*MS)N5EPKU6V M/BVP4O"K9*OPJ0:/Y#@>!# 7H6O5^S#O>:.C ]*;2,Q2@^F7(]EW,#/ M \:S5/DK6HXG[A)(//%]H>-J3 3=A& FR7M(53(H?1VJ-%53NC)4&BCW5SK) M+3,JDB'[H4W_:H=_^:&SVSYXV4I6C-.[>YSN0\C25[J*+P8(EL/IR=7IV\9I=71UGEY^O[L-UFWO=/?KY)5&O,^H"R#X2Y=6@[*W0>!LMF&9E5< M'ECU['9^6IS[/=6S!&RR#DNEU?E2B'KS_N+=O$)RR5#&( MP1%TK--C2K/.SE:X_>STJ1%+)X*Y]$#"\SY#8$=!RN!V9[_77TGF%Q,KQC-( MS85(E$[9EO\N.,0SPJ1,7$-+INFV"+<'=YN%W*IT^X\!OSDP M;8B5^>3P0HREP7),2FGXX3]/+CZPT[/CYGH\;&8>VH\Q[ZV36\ N30"U3>>$ M,VZ8242 ^4W(9,QD:A@8#E ^O?T=QO> \>>P!E)Z[3,&U':LL3O7L6(6BXO>PZ(QUB50D6EUC/^#P#G^7!B@P,EXT9CB- M^T/ XWV^^=?/PCGKA(6T+.>,[U]>*3?[^V_ M6,>G')3J9)I&9"6]*K@&1GJKF]B#GXB3[VX8G/HT1@*],8 MJUU'8:B%,>[76XB".@\O=71KA]W]SBX[:[)W$DAF1Y!490MK*/75N=4JHKH/ M)ZI7.[S,)"@2!![MAY)R#!_?ZRMU$S^92R MX9:;)J8TB09AR(1'3-R*($OE-68Z8!J$V69;P *&/%A=J/EBAJ!(&O_RPUZW M\^+ @+&,1#)1L6 QF>$ZNI,HP^B?]W]C=6Q8L/+=DSE3*CI(D G<"_N+9P?T&[ 2$ M&S9GUV0VX"NWD >(C)@M\('313O$(FY\X:SY/75_@KKV72"K'1Y/1/")"K$\ M 8L.-@DCQZ&Z94,1J1N4&=Y$R;*]QJ]L)"/4<6E X5,1AR#+5($XIUF4\EBH MS$0S9D#;S&A&3[H'U!#88&,>5_@M570RZ =P$L_\O9&*8'!\#KV,Q,C/L"TC M!/M%Q$*#R3R-X=G,5K6/FMVF)7=[L I%NP\N=#QJ(2.O7A05C<72R5QIY7XY M2&U9D:'_T\'2L/613.7O6J8 @S/L]B%M&8Q7!@J%0TY2#0%7"&3]U_T^P>+ MUO2."-Z2GLN65<7)/MO@SNT:J!VZZ0%_RO-C26EAY2(#A/2[.P["AU]?O1"&*9;P:Y M,,=&4)KDG3:WTP\;W:WA]OUP;-M^1_+7A>138S*AO^.9\-P3C?Y6<#\\N[9W MX_G1TX52<&/C=Z$A TB6;34A[73Q/,Q@963^'[ &N?=]"?*++'7<([E>,=>) M3$4#H2# +MQH7E'W]960SA-40J[PV(;=)!1,6!!Q8W)=?=)%BH=R\)G9I3GJ MK%TAN9Q-H=V6V?Y6./84I;8SMRV&\"6-NQYIL&=)]KRM:47_C@:.^:)3"'' M?L?U)Y$^PSIN[? T#C&H%&PX8P'5L^%%^H4&. M[1@/SXJ>D$6 O-$:+.%ZX%)@RH7B_P1@)R+(&@!VL:(<(C."6@$GW1(#'B"6 ME%?8 V7($AHKFN'@-Q*&1G'$0!_):&G@.P,SC ,M@/ AP+QDVQJ/$(=>A ML8L+X:H$IK?%\P2FC-(FRQG^2!G--W?RS*Y:5=>N_EKR]T,!\@-_']WPF?GK MH5VUF^21 21H2@]^V*=_!Y[,Y+92!6E]Z?.!WT:)I]-94>-9OY7I-!53*^!^ M$_<4WF_3U5/77=9%I;804YG6LC3Q3,6-"Q%)?+V FQ8#[3]'$V)7,ZE,%;(W MN2VA[318U3%H:SB#QSE:KZ,LE*D_)P)WT'Y' N^<(B#E%.Y=2W&S2=EF=X6I MIHF"C04JL&JWF>D&PV9EN?CS/>Y)LV=%[ 5_8 0M.KJWV)E',KEH&A,M(*3- MEW9Q!R[:!>)(87]-P3,TW?@@'E1AUKY?"O#JQ9B]?,Q_"IT!]X(FV\)'0GK?RRF*-\X!,T![X9^^D.8CEMU0&' MD9.=3K00="4&(\KH\(UQ\_A'%HOJ%"ITGX/KTDN!E$_%3%06H2-DD0)_H]D0 MG66$1QVR!#@<0MX 3@H[E=6MA,KZ8ZW)_UE$NI8EY^=G8;@M4)R<71V]?G,* M\S0"\1RSHT3+R,E^W\L!'[.Y'6=C#DB AKZ+'SLOZOV=W?I>I\]N.&X, $\- MT4T^ 'A G8SAL3'&.<5V+CY%;EO6@+6TO 1-C(AJ M1(Z7CYPF&?U&^R!,6O=@+05(PA#K&N(P(>)<(I[\I9@O82P# MJZA3$'@Z\X\XIO"AC"!B=40A_VC6QLJZROQ<=0KI>?*(-!6CFA8Z+-B/NW-\ M(]/"S<2) )H-[?X2CRJ 0A I QCW%&AM@TJ/US6P+Q-#?/JQ7W\!3-SM]M9D M&MVGL,UE3>&140NJ@GF=(&W)U=U)9JQ0P]$8"@V60AID2 :X\@U6VY\FN[1' MJ@)2HS)CO2@1-'YW#G"6&[*960H#6,F,(G5CP"^ "H+NF RW,DIA,2QB4IIR MOW!U*H2UUI@V:0!&!D3A2HE,G?4%72EV#I$UABZ0)C )"%,W,< T3$KC#5 < MDO P RS@3LL1^6B7-J"13%DD<.,9[EXD'S0"VU#9JS0J$YKO>=3.L<=V-]2= MD46GW?C-1Q1> _[,Z)S::G>!VIR-,Y-6O:_']!+50PVOFB;DFE-;ED0\1N@$ MKE114D&0%2(IUSOBI3(5:0ZS%/=SDA5!CY_; )"7(E,+H(7HD^PFC0O#0=LY MK^6G#V8M@1&,)[V*6%1&8[ KFJZF)*$^#\;"2B#QINP 6*BR(= Q5%FZ5(2> M@PXXHBMO&ZKG'R\-\JL6Z$K=:11U=Y_JL@DX>H0/50.$#F60!PKNC_ '/@X2^"*0!['RSA_69Z=-WK[3R"Z&--*_&#M_-KX&)O2^!9[ M^3NAPB4\= 9OB<6:BE"Z"!H\R0,,S4JT/(.YL0DZZ7V:"K'*T?^LN*90X;7$ M$!)M#H$13'U6ME P3^,=@.<$.(QC$#X">%.5I'>]6'TD1EU:OXQV8.$BQE^8_$(D.G]KB''@]>)U< QRNNR! M!% LE] #*?R_EM%IA/BTV#L(A5\KO=")PO=D@O%;Y)>-!_/K" PC =U8I;I- M\ B+M=TNEHTQ[;=GMEQ\@K[*WE_RG ?(&AR[6* *EPBZLFZI7FZ+10=-QZWL M0@E*D#OG,E$)<)41XT=X[H;>#4H1/](&/B(%=] PC M:R*)VQK,,I(&;$NZ B,%_>@XP UX9R(J$5[AA$H>ZA%,:=U;D.)@FE\4)85: MZ=K$:(3FX)K\*Y81A;6BF$9B59U.I7@4>2X9.8XI>P9B,:S&Q#<@%NO%F8K/ MCU8(98XX_(B!4D#Q$42T\P'70A9D70,15\Y?*-0@N^&#.(PV"_KG^X9<&[0D MQJ2=TB-;XUY64CH 1)0A 9J_)M&NIN$K(XMR-&'5%0:I "^7DH0!@I0 #V"9 MEGWY(WIMM5RHOA)1=UPE,D!%M=?7(M^N@V[]"<$DI#WU$B.Q8&U7/W&6I236 M'AP5%+!ZO0Z*T@?B>HECDO&UB@#?A07&Y"N;)HX>+0%%H<2-O#EF0%JNNH*%!6<.\ZAQ6CHV.K#I @Q=I%C>,('+\];! M+O&N42FGD%BO1H5VQ0A;?5*H^@$T'V6V//TE#9)'2;G^6S$5*VQ"H:%%3H)] M@#L,1(B*6W?QN^,:J'>F>3"S5^_0M,4\")F-' OQ?>X":^ID$$5XD*<)A90 M2H BC)#QL8BJ1RH>(>>"HD9>)BAPBV*Q.P5]'[)@AF7LX3O95Q58,N^8+$"M M8'%W#M;G@Y4A?V W:AGQNH1!QWSET@!]N4>U3,B+E*XP#5:I M> ,'^,8,1*[T#!>3)\I&E59P!:>MF;JK*?[$0 M(2T8@$1$8M>R*6@AYX:A:50I5!0"61VT4(W:6Y22&2%\U%W)>$9;+81]YPCF M5'6WR&*E)"EZV-2&(.X41DN@[1]3Q.Y-5R%CJ>4F6F[EV-*_)X7;^11JS.MI?NX6$+^^;O M>(OS(^]Q\QMFNM_NYIUG?9?AY>DO9T=7'R[6O G[::HPYW/+R!K_>(3V>U?N M6>1(%_?KA1DH'MGNT,9%NESLPV0([;-]->-03'@T\J: =-HUP!46R$.4[<[Y MQ7^+L+ER8UWWJS\JM.IUA6M/!_5W_$$06\ ?@W%-P3]$R;)'^>#9Z0YDT.!=VQSW=##]0R+?8.4C?J>YT3T73Q?6<]/%+WB^Y^D&)46X]_3"^BPKAM^QG'" M>P]\%$YE3)$E5=S=Z%4;L79_]%>=3_46\JF6_1ML]!?:#O\?4$L#!!0 ( M $"&;U>?E2WJ] ( .\) 1 =F5R=2TR,#(S,3$Q,"YX<@C\I#HY?4L9_"&4E'!NUX<1!X@3T5&^;CKEX(XHC9+#"\VQ"1;%7-+Q1,.G M]#,XU#'<;AB#@84I&*!"^89937BFLD2E$\S)V0< 4QVN$E.?LNM-M"Z2,+0? MQ83(G 2IR!W3.(XC;^4^&TI&E_[3Z32P-X&08^,=M4/*E3;$L %AE/\^@+#F M(5%-Q&P+,FT[0'QQ<1$ZZP:E3"_=F]$[865L>&=:^GI>H-I-R9A#:[9O;_E1 MVV_'33#2]3P*TV LWD)C<-5J^!J!K><9$35T.6K+"D&TEG18:KP7,K_%$2F9 M>5#)_Y2$T1'%S'DAPQRY7O-9]]!$CE$_DAQ505(\I:\JVU5P4\,X_/G0?W:J M\:XL , )B>:%D!HJ/?5%ZH1^H,_VRZ_EX=LK/VZ9\@8FF =\B_,!;4'X;B*U MZOZ)R%*R[R%2:],RZ.S+O5/,1V=51ZC;?:NCWKYK-D[BLG-D[,&WAX,UV!JT M16*7EG NM,O5)$.*@O*16%R92]NVI.[= $?@-DE"9"H%P\/[)BRD*%!J:L9V MU?XJP$3BJ.O9&?/KR?K%R# PDU6[;"58%Y0UAP:"K+^B5V,UU1;LJ4GC4$^9^?6T@\];D&HLPV\RW RR&;]4F'WG5^Z<$I:6;%GM!7CA<0BX MV:?CD2MF^W&+V[I3]?R&FP.\N&D.>G55[1KS^1=02P,$% @ 0(9O5[]J M#G=;!@ E48 !4 !V97)U+3(P,C,Q,3$P7VQA8BYX;6S-G&]OVS80QM\7 MZ'>X>6\V8+)C!T57HVD1N,D0+&V"QMV,A2XQ-3"8-4D[L;S]2?QHYIF0J M/%9YDR@B[[E[[-\QC"3G[?O-,H$[(B3E[*0W[!_U@+"(QY3-3WIK&80RHK0' M,@U9'":ELC>^WAH= S# MT?CH]?C5:[C^"&>A3(E@,*5+4@WFJZV@\T4*/T4_0Q9E4]MIDL!G'2;A,Y%$ MW)&X+#BA[+^Q_C(+)0%X^0) O69,9N=.>HLT78T'@_O[^_YF)I(^%W-5[-'Q MH SI/41L]D+NC[. X9LW;P;9:'6VI*:Y2GPX^.OCY4VT(,LPH$R_-U&11M*Q MS,Y?\BA[$2T*A-H9^J>@G!;H4\%P%!P/^QL9]][IA,6K$\Y((B_)D9N*D9P@:[!:DYYV*:$YFPX,O-(:^Y M4-68()*OA<*KS5N;^7F7*<,_I?:_;P2R;;UN2'[@T7I)6#I5 M5=L2N1O3$9#&POG^F N.^SI(-);"H)6=4<0OLTJB9:TX&%X307E\QN(/ZM=M M6QX?!7<,IMD*;YB$@:I!$)O9/ 6H'*"3H.'KH70CQ];UNR%]QE*:;C^3.=5+ M.$L_A4MKHLVQ'0'=:(37SW'!N5X/B>8\ 3QD )W"F65_=5=1;EL\!LCJ+Q,N M5EQD&_F;5#7.A*]9*K83'K?D^H!4IYC;V>36(>Y-8"&/VQ,["2'+"$5*T#F1 MFN0[^#+TS-/-8331.4W(I_5R1D2[CJG&==H>!@/8B5ILE>DOS2S=/H;96I%.$#UGC%I/=X6X4QB5=I8+=7+C< M>[5B:((G^,%HB=,X5@9D\>V2,C)LUPY&@4Y;H) M8(C$OC MB2F_9T]"OAK^'( WV#'A_C -#?;'DGY0UUG@2H#.@PLZ=OT-F-N90(0\^POX M2EP+?D=9U/)"3IW&<\"]SIB)^4=ST< WZOJA/[^2H<@ID^&V@!$Y-(+9E*D-=F:B-8%!U4\+Y(E 9<*\3.G/10/^UE8< MGT?1_@0)V^"^&]/5TRBFPOG^F-.S*'LZ2-AFO^.U,@ZF^'7N/(=B6:P;B/H! ML>1ZP5G+J^/[<1T!66N F\==P#1K(<&9B4.FCG65T$^]54C;%.T&ZI^"IBEA M$[Y!L$D0@N,L!N"F>*/19>1;EM]6XXW_"$ M1C2E;/Y1[;<%#1-;EDV1'8'<8(+7S7!!N$X-B=\'>2CUG>'U57*5W%9UNV%[ M+8CN#Z*PR)Y[U$]JBZO;6_N-0Y-"1QA;F.*'9KI@?4@5"6^5!JIY($\$629G MT'V;J +_1">HZ%](N2;"O0$,.L^C#>H-FIMA;SYB2]1H^VJ,/)W7_O#DJ+%+ M6MERW-Z0:*WV4]OA:#:E:6)]C6,_KJNM39T!;AYWVM88M; V-84X*'7(Y-WW M-%[JW=G1M"C:#=2I"/6''&^VRQFWWH(_"NH(47/IW##H J=!"(G,0AER:6/P=C'=W7PUY+RPPX'UWP5[=Q M3;4L'N/NWMF2B+GJFM\$OT\7:C.R"MFVW>V]&HE.[^\UV^('I[K?X6N016*] MN"]6)H(\$Q2ID&[Q>;1AN,?7VHM;"YRJ37>L-][G23BWA?Y14$>8FTOGAD$7 ME U"2/!^4P8M[0RKAT*K>-I6B[$B3U0:$287ZD_ S>^DY5J\%]SI*EQGA3=, M2C>LLX?KKYZX5$?Z'ZP4IVC^;T;4F?\!4$L# M!!0 ( $"&;U=1P\6^HP0 "0L 5 =F5R=2TR,#(S,3$Q,%]P&ULU9I=C^(V%(;O5]K_X*8WK=00$G9V=M P*\3.5*CS@0:VK7I3F>0 5AT[ MLLT _[YVP+,)A%DRVZUB+DAP_!Z_/H])'">7'] Q3PA M;-[SEM+',B;$0U)AEF#*&?2\#4COX]7;-Y<_^#[Z=#.\1WK#&0-*88-N",,L M)IBB,:=+I%8"-#B5801>%81"> M!5$[ZJ PZK;/NV?OT>@.76.I0# T(2D4Q3S;"#)?*/13_#/*5:=XZU.*'HU, MHD>0()X@L88I8?]TS=<42T#H[1ND/SIK3.:E/6^A5-8-@M5JU5I/!6UQ,==V MVYW BKRB9GT@6G5R27AQ<1'D1\OU):FJK1L(@S_O;L?Q E+L$V8(Q7M-:3>) M>E87S9T%VX.VOB1=F4>ZY7&>_!.ZA8[6,+]\6\TW17X8^9VPM9:)=V6:W&95 M< J/,$-F^_EQ^-RF'H_+;(%%BELQ3X,4!+!6P!)(;!CC_;MT]6H+5SJNFE/VE$@(6[-^5.0 ,E; M-#MY7O*16BX+\T9'L^T1Y.]5/6 ME.T4D?5%7(J(16RCZ=T2K\/!OJL19%CH>'Z\(/09]4SPM#(UN]9XE4\N$A ] M+VJW]'_<0YD@7&C2NL1#2ZFM\,R8QM0<@QD( 8.]?E20E[S.[$9 M@?:J!V;R29^YZT+:$S>?UIYABRUT!MOV#/((A7[%O '<< WQ *]\MT"J(> MS:*NZ>B*7BVG=XYQFN#U,-%I(#.RG3>_!MK1($TG>-2XQ7GF&,Y^DN@DR]U& MS^0AK(>R,D#3,5::M@C?.X\P^E:$D8L(HQ+"T$&$ [W[("9\Q5X%L"AW!%_1 M<@%>QT%X^53L08P$?R)F7>HU! ]B.(+QP/<7EJ&++$=<*DS_(EG]NXOJ"(YP MW'/]A6+D"$5S/ND+P'6XE37-)57VN6/3<6?QQ2RTT]&"LYKW>8>ZYC(Z]%K@ MY,B4Y _M3P$;\#1=LMUMCCP5UA%QB^YMA3=64/9 MZ\U0RB6(;V=9$<<9HA7>+5=W%E;&$"^-Q3":3HBB)T\E#W7-Y7;HU7(Z=X;3 M1&#SWLYXDT[YR9>[/5%S">T9M7@^.(/'#K'K=;S ; YU'K=6:YL+J]JO97;A M#+/M>L!U"F*NQ]ZO@J_40I_?,\PV]19"CH1H+L$7;>] OG/G%96^OAHGYHI\ M0_'\5'1[HN;"VC-J\;BS&K(=;0/= X'I4,^6UK]!S7_8@;BYN(X8MMC^A[=1 M+H.#I-SJ O.^Z_:(^3)O;^J2?P%02P$"% ,4 " ! AF]7$M GM_$5 W M<0 #@ @ $ 9#@U,#8Q,60X:RYH=&U02P$"% ,4 M" ! AF]7GY4MZO0" #O"0 $0 @ $=%@ =F5R=2TR,#(S M,3$Q,"YX&UL4$L! A0#% @ 0(9O M5U'#Q;ZC! )"P !4 ( !SA\ '9E